Search

Author/Creator Albertini, Mark

1. 312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition. (9th November 2020)

Authors:
Tarhini, Ahmad; Kang, Ni; Lee, Sandra; Stephen Hodi, F; Cohen, Gary; Hamid, Omid; Hutchins, Laura; Sosman, Jeffrey; Kluger, Harriett; Eroglu, Zeynep; Koon, Henry; Lawrence, Donald; Kendra, Kari; Minor, David; Lee, Carrie; Albertini, Mark; Flaherty, Lawrence; Petrella, Teresa; Striecher, Howard; S...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A339
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α, 24(S)Dihydroxyvitamin D2) in patients with advanced cancer. (December 2015)

Authors:
Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill; Wilding, George; Liu, Glenn; Douglas, Jeffrey; Traynor, Anne M; Albertini, Mark; Mulkerin, Daniel; Bailey, Howard H
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 21:Number 6(2015)
Page Start:
416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗